AbbVie Inc. logo

AbbVie Inc. (ABBV)

Market Open
13 Aug, 16:48
NYSE NYSE
$
250. 94
+2.18
+0.8763%
$
434.7B Market Cap
42.2 P/E Ratio
1.58% Div Yield
2.03M Volume
10.28 Eps
$ 248.76
Previous Close
Add Transaction
Day Range
249.87 255.29
Year Range
190.75 267.47
Want to track ABBV and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
7 High-Yield Dividend Stocks to Help Pay Your Bills

7 High-Yield Dividend Stocks to Help Pay Your Bills

While active acquisition is perhaps the most common methodology of gaining wealth, it's not always the most efficient. For example, even if you trade your hours for a generous paycheck, there are only so many hours available: in a day, in a week, in a month, you get the idea.

Investorplace | 2 years ago
3 Absurdly Cheap Stocks to Buy and Hold for Years

3 Absurdly Cheap Stocks to Buy and Hold for Years

Drugmaker AbbVie has been investing in its growth, and that strategy looks to be paying off. Verizon's stable business and low valuation make it practically a no-brainer buy for dividend investors.

Fool | 2 years ago
7 High-Yield Dividend Stocks Beating Inflation

7 High-Yield Dividend Stocks Beating Inflation

At this writing, current inflation rate is 3% over the past 12 months. That's the reading as of the end of June.

Investorplace | 2 years ago
7 Recession-Proof Stocks to Shield Your Portfolio in 2024

7 Recession-Proof Stocks to Shield Your Portfolio in 2024

U.S. News & World Report recently said the New York Fed's Recession Probability model hints that within the next 12 months, we stand a 55.8% chance of a recession. One can never be too safe though.

Investorplace | 2 years ago
AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU

AbbVie (ABBV) Files for Rinvoq in Giant Cell Arteritis in US & EU

AbbVie (ABBV) files regulatory applications to the FDA and the EMA, seeking approval for a new indication of Rinvoq, giant cell arteritis.

Zacks | 2 years ago
Wall Street Brunch: Trump 'Fine' After Shooting

Wall Street Brunch: Trump 'Fine' After Shooting

Trump confirms he is "fine" after assassination attempt during rally in Pennsylvania, suspect dead. Global leaders condemn violence, wish Trump speedy recovery.

Seekingalpha | 2 years ago
3 Dividend Growth Stocks to Buy and Hold

3 Dividend Growth Stocks to Buy and Hold

AbbVie is poised to keep a 52-year streak of dividend hikes going. Amgen offers more than a dividend with its promising pipeline.

Fool | 2 years ago
3 High-Yield Dividend Stocks That Still Look Like Bargains

3 High-Yield Dividend Stocks That Still Look Like Bargains

Johnson & Johnson and AbbVie produce reliable earnings driven by sales of patent-protected drugs. Real estate investment trust Agree Realty makes monthly dividend payments.

Fool | 2 years ago
AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?

AbbVie (ABBV) Up 24% in a Year: Buy, Sell or Hold the Stock?

Investors who own AbbVie's (ABBV) stock may stay invested as the company has faced its biggest challenge, Humira's patent cliff- quite well and looks set to return to robust growth next year.

Zacks | 2 years ago
5 High-Yield Dividend Champions to Buy Hand Over Fist Now

5 High-Yield Dividend Champions to Buy Hand Over Fist Now

Dividend stocks are a favorite among investors for good reasons.

247wallst | 2 years ago
Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks | 2 years ago
The Smartest Dividend Stocks to Buy With $250 Right Now

The Smartest Dividend Stocks to Buy With $250 Right Now

One of these stocks is a Dividend King poised to deliver solid growth for years to come. Another offers an ultra-high dividend yield of 9.2% and has a big growth opportunity.

Fool | 2 years ago
Loading...
Load More